MRIs help predict which atrial fibrillation patients will benefit from catheter ablation

February 4, 2014, Loyola University Health System

A new type of contrast MRI can predict which heart patients with atrial fibrillation are most likely to benefit from a treatment called catheter ablation, according to a landmark multi-center study published in the Journal of the American Medical Association.

Loyola University Medical Center had the second highest enrollment in the international study, contributing 15 percent of the . David Wilber, MD, director of Loyola's Division of Cardiology and Section of Clinical Electrophysiology, is second author. First author is Nassir Marrouche, MD of the University of Utah School of Medicine.

Atrial fibrillation, or A-fib, is the most common type of arrhythmia (irregular heartbeat). It's caused by erratic electrical signals in the heart. When medications don't work, A-fib often can be controlled with catheter ablation, in which a catheter burns away heart tissue responsible for the erratic signals. Catheter ablation does not work for all patients, however, and there has not been a reliable way to predict which ones will benefit.

Researchers enrolled 329 patients from 15 centers in the United States, Europe and Australia. Each underwent a . Less than 30 days before their ablations, the patients also underwent a new type of imaging test called delayed enhancement-magnetic resonance imaging (DE-MRI) of the upper chamber of the heart (left atrium). The imaging shows of the wall of the left atrium called atrial fibrosis.

Researchers excluded 69 patients because their DE-MRIs were of insufficient quality or because researchers lost track of them during follow-up. That left 260 patients. After 475 days of follow up, patients with the least amount of scarring had significantly higher ablation success rates.

The pre-ablation DE-MRIs showed the amount of scarring in the , one of the heart's two upper chambers. Scarring ranged from Stage 1 (covering less than 10 percent of the atrial wall) to Stage 4 (covering more than 30 percent of the atrial wall).

After 475 days of follow up, 85 percent of patients with the least-severe Stage 1 scarring had experienced no recurrent arrhythmias. The success rate dropped to 64 percent for patients with Stage 2 scarring, 54 percent for patients with Stage 3 scarring and only 31 percent for patients with the most severe Stage 4 scarring.

"Catheter ablation is a very effective treatment for atrial fibrillation, but it can't cure everyone," Wilber said. "The findings from this study suggest there may be patients whose scarring is so advanced that ablation in its current form is much less likely to be effective as a single procedure. In such cases, patients, in consultation with their physicians, may decide to forgo ablation, or be prepared to have more than one procedure to control the arrhythmia."

Patients unlikely to benefit from ablation still could be treated with medications, and in some circumstances with pacemakers, Wilber added.

Loyola is the only center in the Midwest that offers this new type of DE-MRI for A-fib patients. DE-MRI uses sophisticated imaging techniques to acquire and process images. "DE-MRI enables us to look at not just the heart size and function, but also structural changes in the heart, such as fibrosis, that can better inform treatment decisions," said Mushabbar Syed, MD, Loyola's Director of Cardiovascular Imaging. These advanced imaging technologies, along with expert arrhythmia specialists, make Loyola a unique center for A-fib patients.

The study also suggests that earlier treatment may be beneficial, since the longer a patient experiences A-fib, the more scarring the patient is likely to have. But this would need to be confirmed by further studies, Wilber said.

Patients in the study also underwent DE-MRIs 90 days after their catheter ablations. These follow-up scans showed physicians how effective the ablations had been in burning troublesome scar tissue. Such findings could help guide physicians if and when additional ablations are necessary, Wilber said.

More than 2 million Americans have , and there are about 160,000 new cases each year. The number is increasing, due in part to the aging population and the obesity epidemic. A-fib is the most common form of . Electrical signals, which regulate the heartbeat, become erratic. Instead of beating regularly, the upper chambers of the heart quiver. Not all the blood gets pumped out, so clots can form. A-fib can lead to strokes and heart failure. A-fib symptoms include palpitations, dizziness, chest pain, fatigue, shortness of breath, fainting and lightheadedness.

Explore further: Magnetic resonance imaging before ablation for atrial fibrosis helps predict success of treatment

Related Stories

Magnetic resonance imaging before ablation for atrial fibrosis helps predict success of treatment

September 1, 2013
In patients with atrial fibrillation, delayed enhancement magnetic resonance imaging (DE-MRI) performed before ablative treatment can stage the degree of damaged heart tissue (atrial fibrosis) and help predict whether treatment ...

Loyola testing new device for treating Atrial Fibrillation

September 15, 2011
Loyola University Medical Center is testing a high-tech catheter device that's intended to improve outcomes of patients treated for atrial fibrillation, the most common irregular heartbeat.

Beaumont Health System first outside of Japan to test new atrial fibrillation technology

January 31, 2014
Beaumont Health System is the first center outside of Japan to use a new balloon ablation technology to treat atrial fibrillation, the most common heart rhythm disorder that affects about 3 million people in the U.S.

High frequency source ablation effective in treating atrial fibrillation

November 20, 2013
High frequency source ablation is as safe and effective as a more standard ablation treatment for patients with paroxysmal atrial fibrillation, according to a late-breaking clinical trial presented at the American Heart Association's ...

Recommended for you

A nanoparticle inhalant for treating heart disease

January 18, 2018
A team of researchers from Italy and Germany has developed a nanoparticle inhalant for treating people suffering from heart disease. In their paper published in the journal Science Translational Medicine, the group describes ...

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.